This company is very asset rich (industrial property),the recent and medium term charts are now excellent and trading could not get any worse than last year in that they are moving a lot of production to low cost Eastern Europe and moving away from their total dependence on tabacco machinery.

The charts have since turned negative

ONE TO WATCH AT 78p

Write this one down.. the net asset value is worth 5 times the current capitalization

Results due on 25th August as per the news Thursday. All pointers indicate they will be strong I hear.

For anyone interested this was the March 2011 write up. Expectation is the forecasts for this year could well be exceeded.

http://www.mediafire.com/?quy59m7m9qlv5kn


.

Positive results out and progress made.

http://www.investegate.co.uk/Article.aspx?id=201108250700199961M

.

Another nice set of results !!

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11130472

.

Molins profits paper thin as first-half numbers disappoint
Date: Friday 31 Aug 2012


Molins, which produces cigarette making equipment and packaging machinery, has reported a steep fall in pre-tax profits but insists its performance will improve in the second half.

Group sales in the six months to June 30th were £39.9m, down only slightly on the £38.8m the year before. However, underlying operating profit was just £0.8m compared to the £1.7m seen at the same point last year.

Underlying earnings per share came in at 3.6p (2011: 6.3p) while net funds at June 30th were £5.7m down from the £7.1m reported at the end of 2011.

On a brighter note, Molins says orders are 14% up on the prior year.

Chief Executive Dick Hunter commented: "As indicated previously, group trading performance will be strongly second half weighted and the board's expectation of performance for the full year remains unchanged.

The market was not impressed however; at 10:11, the stock had fallen 12.6%.

Analyst Michael O'brien from Canaccord Genuity met with the company's management a fortnight ago. The company is expected to report flat adjusted pre-tax profits of £4.5 m and EPS of 17.7p in 2012, but notes that ''these estimates could prove conservative''.

Molins is smoking -


A buy in this weeks IC- Molins does most of its work for the tobacco industry, but it was the high -speed packerging machinery business that impressed most in 2012.Profit there tripled to £1.5m and a 5% increase in the order book improves visibility. Caaccord Genuity now thinks the shares could be worth 200p. But its the scientific services unit thats set to excite. Molins with two thirds of the market, should make a fortune when a new stricter regime is introduced in the US. Expect an announcement in April.

http://www.edisoninvestmentresearch.co.uk/researchreports/Molins040313review.pdf

A buy in this weeks Shares mag, a double page feature.

Molins, a firm that makes machinery for the tobacco industry as well as analysing and testing cigarette smoke, is holding its own in tough markets.

The American government is tightening regulations meaning that tobacco products will have to pass tougher tests, which is good news for Molins.

Molins has invested heavily in new laboratories and has also won a significant share of the new tobacco smoke testing business which should see profits start to increase.

Money Week's Verdict: The shares are risky but worth a punt. Buy at 168p.


Read more: http://www.dailymail.co.uk/money/investing/article-2302804/Newspaper-magazine-share-tips-Sainsburys-Molins-Capita-MP-Evans-London-Mining-Standard-Chartered-BTG-Dunelm-EnQuest.html#ixzz2PiF2nxpW
Follow us: @MailOnline on Twitter | DailyMail on Facebook

http://www.dailymail.co.uk/money/investing/article-2302804/Newspaper-magazine-share-tips-Sainsburys-Molins-Capita-MP-Evans-London-Mining-Standard-Chartered-BTG-Dunelm-EnQuest.html

:-))

Good rise today, tipped by IC to rerate,

Molins schedules interims 25 July 2013 | 13:50pm StockMarketWire.com - Molins will be announcing its results for the six months to the end of June on 29 August. At 1:50pm: [LON:MLIN] Molins share price was -0.5p at 173p

Final Results

Group Highlights

· Order intake maintained at same levels as last year

· Increase in Group sales of 20% to £47.8m (2012: £39.9m)

· Increase in Group underlying profit before tax to £1.5m (2012: £0.8m)

· Underlying earnings per share increased to 6.5p (2012: 3.6p)

· Net funds of £5.6m

· Interim dividend per share maintained at 2.5p (2012: 2.5p)



http://www.moneyam.com/action/news/showArticle?id=4658225

IC's Simon T. today - A share ready to smoke

Investors are playing a waiting game at specialist engineer Molins

(MLIN: 165p) and I am happy to bid my time too.

To recap, around 60 per cent of sales come from the tobacco industry, where Molins specialises in improving the effectiveness of existing customer plant, monitoring and testing product quality and conducting the analysis of cigarette smoke. This is the high-end part of the business, accounting for a quarter of revenues, and a likely source of some exciting news if, as expected, Molins' tobacco testing business, Arista Laboratories, receives a boost in demand for its services resulting from tighter US regulations that are expected to be implemented by the Food & Drug Administration (FDA).

The US regulator has already heard representations from cigarette manufacturers in advance of issuing guidance on testing requirements with a view to tightening up the testing regime for harmful compounds found in tobacco smoke. The new regulations were scheduled to be published in April, but have been delayed and the latest indication from the FDA is that guidance will be published in December. This largely explains why Molins' shares have been trading sideways since February, having enjoyed a bumper performance in the previous 12 months after I included them in my 2012 Bargain Share Portfolio.

True, the timescale and nature of the FDA testing regime is uncertain, but what is not in doubt is that Molins is well-placed to capitalise on the opportunities, especially as Arista has a significant logistical and marketing advantage to attract new business for its onshore US testing services. The unit is fully operational from its new laboratory facility in Richmond, Virginia, where it services all the tobacco industry's tobacco and smoke testing requirements, and from where non-tobacco testing will be carried out as the business extends its activities into other end markets.

Analyst Michael O'Brien at broking house Canaccord Genuity believes that several major tobacco manufacturers, which currently do the testing of these compounds in-house, will have to outsource much of it in future if the FDA dramatically expands the number of harmful compounds on its consultation list. In my view, any forthcoming FDA-related newsflow will be a key share price driver for Molins if, as expected, the regulator does extend the list of harmful compounds that tobacco companies need to test. It would also prompt analysts to upgrade their earnings estimates for future years.


Lowly valued

But even without upside from a change in US legislation, Molins is performing well enough if last week's half-year results are anything to go on. In fact, the company grew sales by 20 per cent to £47.8m and almost doubled underlying pre-tax profits from £0.8m to £1.5m. For the full year, Canaccord forecasts that Molins will raise operating profits by 10 per cent to £5.5m, mainly reflecting the heavy second-half bias to the reported numbers. Guidance from the company's management is that the business is trading in line with these forecasts.

True, a higher tax charge means underlying EPS is likely to flat at 22p, but this is unlikely to hold back the dividend, which is expected to rise to 5.7p a share, having been raised from 5.3p to 5.5p last year. On that basis, the shares trade on a miserly 7.5 times forward earnings and yield around 3.3 per cent. That is a pretty attractive rating, which becomes even more compelling once you consider that Molins had net funds of £5.6m, worth 28p a share, at the end of June. Strip this cash out from the share price and the multiple drops to a bargain basement six times earnings. For good measure, the shares trade on a hefty 25 per cent discount to net asset value of 211p.


Positive technical set up

The technical set-up is certainly supportive of another leg up in the company's share price and a rally back to the August 2007 bull market high around 220p. The 14-day relative strength index (RSI) is neutral after a modest pull-back from the mid-July high of 177p, and the price is not overextended, trading just above the 200-day moving average around 159p. Interestingly, the long-term trend line has acted as support for the share price for the past couple of years and each time it has been tested has been the precursor to a major rally. There is little to expect any difference this time around.

Needless to say, I remain a buyer of Molins' shares on a bargain basement six times this year's earnings estimates net of cash. My target price remains 220p - equating to 8.7 times earnings estimates net of cash - which I feel could be achieved by the year-end assuming of course the FDA releases its guidance by then. Offering 33 per cent potential upside to my target price, I continue to rate Molins' shares a value buy on a bid-offer spread of 163p to 165p.

Starting to stir.